Targeting the Wnt Signaling Pathway for Breast Cancer Bone Metastasis Therapy

Overview

Journal J Mol Med (Berl)

Specialty General Medicine

Date 2021 Nov 25

PMID 34821953

Citations 1

Authors

Jingyao Cui

Haoran Chen

Kaiwen Zhang

Xin Li

Affiliations

Soon will be listed here.

Abstract

Osteolytic bone destruction is found in approximately 60% of advanced breast cancer patients. With the pathogenesis of bone metastasis being unclear, traditional antiresorptive therapeutic strategies might not be ideal for treatment. The Wnt pathway is a highly organized cascade involved in multiple stages of cancer bone metastasis, and Wnt-targeted therapeutic strategies have shown promise in achieving favorable outcomes. In this review, we summarize the current progress of pharmacological Wnt modulators against breast cancer bone metastasis, discuss emerging therapeutic strategies based on Wnt pathway-related targets for bone therapy, and highlight opportunities to better harness the Wnt pathway for bone metastasis therapeutics to further reveal the implications of the Wnt pathway in bone metastasis pathology and provide new ideas for the development of Wnt-based intervention strategies against breast cancer bone metastasis.

Citing Articles

Wnt/β-catenin-driven EMT regulation in human cancers.

Xue W, Yang L, Chen C, Ashrafizadeh M, Tian Y, Sun R Cell Mol Life Sci. 2024; 81(1):79.

PMID: 38334836 PMC: 10857981. DOI: 10.1007/s00018-023-05099-7.

References

Goldvaser H, Amir E . Role of Bisphosphonates in Breast Cancer Therapy. Curr Treat Options Oncol. 2019; 20(4):26. DOI: 10.1007/s11864-019-0623-8. View

Chandran T, Venkatachalam I . Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review. Singapore Med J. 2019; 60(7):364-378. PMC: 6658653. DOI: 10.11622/smedj.2019028. View

Hart I . 'Seed and soil' revisited: mechanisms of site-specific metastasis. Cancer Metastasis Rev. 1982; 1(1):5-16. DOI: 10.1007/BF00049477. View

Kobayashi Y, Uehara S, Udagawa N, Takahashi N . Regulation of bone metabolism by Wnt signals. J Biochem. 2015; 159(4):387-92. PMC: 4885935. DOI: 10.1093/jb/mvv124. View

Li X, Yang J, Bao M, Zeng K, Fu S, Wang C . Wnt signaling in bone metastasis: mechanisms and therapeutic opportunities. Life Sci. 2018; 208:33-45. DOI: 10.1016/j.lfs.2018.06.036. View

MacDonald B, Tamai K, He X . Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009; 17(1):9-26. PMC: 2861485. DOI: 10.1016/j.devcel.2009.06.016. View

Logan C, Nusse R . The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004; 20:781-810. DOI: 10.1146/annurev.cellbio.20.010403.113126. View

Prestwich T, MacDougald O . Wnt/beta-catenin signaling in adipogenesis and metabolism. Curr Opin Cell Biol. 2007; 19(6):612-7. PMC: 2709272. DOI: 10.1016/j.ceb.2007.09.014. View

Ross S, Hemati N, Longo K, Bennett C, Lucas P, Erickson R . Inhibition of adipogenesis by Wnt signaling. Science. 2000; 289(5481):950-3. DOI: 10.1126/science.289.5481.950. View

10.

Xi Y, Chen Y . Wnt signaling pathway: implications for therapy in lung cancer and bone metastasis. Cancer Lett. 2014; 353(1):8-16. DOI: 10.1016/j.canlet.2014.07.010. View

11.

Niida A, Hiroko T, Kasai M, Furukawa Y, Nakamura Y, Suzuki Y . DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene. 2004; 23(52):8520-6. DOI: 10.1038/sj.onc.1207892. View

12.

Scimeca M, Trivigno D, Bonfiglio R, Ciuffa S, Urbano N, Schillaci O . Breast cancer metastasis to bone: From epithelial to mesenchymal transition to breast osteoblast-like cells. Semin Cancer Biol. 2020; 72:155-164. DOI: 10.1016/j.semcancer.2020.01.004. View

13.

Lambert A, Pattabiraman D, Weinberg R . Emerging Biological Principles of Metastasis. Cell. 2017; 168(4):670-691. PMC: 5308465. DOI: 10.1016/j.cell.2016.11.037. View

14.

Evenepoel P, DHaese P, Brandenburg V . Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int. 2015; 88(2):235-40. DOI: 10.1038/ki.2015.156. View

15.

Braig S, Bischoff F, Abhari B, Meijer L, Fulda S, Skaltsounis L . The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer. Biochem Pharmacol. 2014; 91(2):157-67. DOI: 10.1016/j.bcp.2014.07.009. View

16.

Damiens E, Baratte B, Marie D, Eisenbrand G, Meijer L . Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene. 2001; 20(29):3786-97. DOI: 10.1038/sj.onc.1204503. View

17.

Braig S, Kressirer C, Liebl J, Bischoff F, Zahler S, Meijer L . Indirubin derivative 6BIO suppresses metastasis. Cancer Res. 2013; 73(19):6004-12. DOI: 10.1158/0008-5472.CAN-12-4358. View

18.

Chen W, Mook Jr R, Premont R, Wang J . Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2017; 41:89-96. PMC: 5628105. DOI: 10.1016/j.cellsig.2017.04.001. View

19.

Jiao Y, Chen C, Hu X, Feng X, Shi Z, Cao J . Niclosamide and its derivative DK-520 inhibit RANKL-induced osteoclastogenesis. FEBS Open Bio. 2020; 10(8):1685-1697. PMC: 7396435. DOI: 10.1002/2211-5463.12921. View

20.

Cheon Y, Kim J, Baek J, Ahn S, So H, Oh J . Niclosamide suppresses RANKL-induced osteoclastogenesis and prevents LPS-induced bone loss. Biochem Biophys Res Commun. 2016; 470(2):343-349. DOI: 10.1016/j.bbrc.2016.01.048. View